PDCD1 and neoplasm: Unlike previous studies [25,26], our study combined both radiomic features and multiple immune markers, enabling a more comprehensive understanding of the tumor immune microenvironment and providing a multidimensional perspective for predicting the efficacy of PD-1 inhibitors and patient prognosis.